Christopher J. Coughlin Acquires 10,000 Shares of Allergan PLC. (AGN) Stock

Allergan PLC. (NYSE:AGN) Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, for a total transaction of $1,633,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Allergan PLC. (AGN) opened at $168.00 on Thursday. Allergan PLC. has a 52 week low of $160.07 and a 52 week high of $256.80. The company has a market cap of $54,636.75, a PE ratio of 10.65, a P/E/G ratio of 1.10 and a beta of 1.11. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the prior year, the business earned $3.32 EPS. Allergan’s quarterly revenue was up 11.4% on a year-over-year basis. equities analysts forecast that Allergan PLC. will post 16.28 earnings per share for the current year.

Allergan declared that its Board of Directors has initiated a share buyback program on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be paid a $0.70 dividend. The ex-dividend date is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.67%. Allergan’s dividend payout ratio (DPR) is currently -12.44%.

Large investors have recently made changes to their positions in the business. Howard Hughes Medical Institute acquired a new position in shares of Allergan during the 2nd quarter worth approximately $103,000. Cable Hill Partners LLC grew its position in shares of Allergan by 255.2% during the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. grew its position in shares of Allergan by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares in the last quarter. Jacobi Capital Management LLC grew its position in shares of Allergan by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares in the last quarter. Finally, Massey Quick & Co. LLC grew its position in shares of Allergan by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares in the last quarter. Hedge funds and other institutional investors own 81.34% of the company’s stock.

AGN has been the topic of several analyst reports. Citigroup reissued a “buy” rating and set a $280.00 price target on shares of Allergan in a research report on Wednesday, September 20th. Deutsche Bank set a $251.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Piper Jaffray Companies set a $227.00 price target on shares of Allergan and gave the stock a “hold” rating in a research report on Friday, October 6th. J P Morgan Chase & Co reissued a “buy” rating and set a $275.00 price target on shares of Allergan in a research report on Monday, October 16th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $285.00 price target on shares of Allergan in a research report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. Allergan has an average rating of “Buy” and a consensus target price of $241.56.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/07/christopher-j-coughlin-acquires-10000-shares-of-allergan-plc-agn-stock.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit